Ekdv-691 Today

| Milestone | Date | Notes | |-----------|------|-------| | (internal) | Q2 2025 | Proof‑of‑concept silicon, cryogenic validation. | | EKDV‑691 Beta (limited partners) | Q4 2025 | Integration with IBM‑Quantum System One, early‑stage software SDK. | | General Availability (GA) | Q2 2026 | Full production silicon, supported by Ekard’s Quantum‑Ready SDK (QR‑SDK 2.0) . | | EKDV‑691‑X (next‑gen, 128‑core QRC) | Q4 2027 | Targeting 100‑qubit quantum modules. |

As the world waited with bated breath for EKDV-691 to hit the shelves, one thing was clear: this little device had the potential to change the game. EKDV-691

| Study | Model | Dose / Regimen | Key Findings | |-------|-------|----------------|--------------| | | Human primary lung fibroblasts (TGF‑β1‑stimulated) | 0.1–100 nM | Dose‑dependent ↓ α‑SMA, collagen‑I, fibronectin; EC₅₀ ≈ 15 nM | | DDR1‑dependent migration | Collagen‑I coated Boyden chamber with DDR1‑expressing CAFs | 10–500 nM | 80 % inhibition of migration at 100 nM | | Bleomycin‑induced lung fibrosis (C57BL/6 mice) | 10 mg/kg PO q.d. (14 d) starting day 7 post‑bleomycin | ↓ hydroxyproline content by 62 %; histology: ↓ Ashcroft score (3.1 → 1.1) | | Unilateral ureteral obstruction (UUO) renal fibrosis (rats) | 30 mg/kg PO q.d. (21 d) | ↓ renal collagen deposition by 48 % and preserved GFR | | Patient‑derived xenograft (PDX) of desmoplastic pancreatic cancer | 30 mg/kg PO q.d. + gemcitabine | Tumour volume reduction 55 % vs. gemcitabine alone; stromal α‑SMA density ↓ 70 % | | Safety pharmacology | hERG assay, CNS battery, cardiovascular telemetry in dogs | No QTc prolongation at 30× human Cmax; no CNS behavioural changes | | GLP toxicology | 4‑week repeat dose in rat & dog | NOAEL: 100 mg/kg (rat), 60 mg/kg (dog). No target‑organ toxicity, no mutagenicity (Ames, mouse micronucleus). | | Milestone | Date | Notes | |-----------|------|-------|

Ekard Technologies has already signed with two major cloud providers (Azure Quantum and Google Cloud) to make EKDV‑691 accessible via a “Quantum‑Ready as a Service” offering. | | EKDV‑691‑X (next‑gen, 128‑core QRC) | Q4